Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pathogen-specific CTLs
- Development stage
- Unknown
- Lead developer
- Shenzhen Geno-Immune Medical Institute
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Pathogen-specific CTLs, developed by the Shenzhen Geno-Immune Medical Institute, are an adoptive cell therapy consisting of ex vivo expanded cytotoxic T lymphocytes (CTLs) designed to target and eliminate cells infected with specific opportunistic pathogens. This therapeutic approach is primarily intended for immunocompromised patients, such as those undergoing hematopoietic stem cell transplantation (HSCT) or solid organ transplantation, who are at high risk for severe infections. The CTLs are trained to recognize antigens from multiple pathogens, including Cytomegalovirus (CMV), Epstein-Barr virus (EBV), Adenovirus (ADV), BK virus (BKV), as well as Mycobacterium tuberculosis and various fungi. By infusing these functional, antigen-specific immune cells, the therapy aims to restore cellular immunity and control infections that may be resistant to standard antimicrobial or antiviral drugs.
- Other names
- Antigen-specific Cytotoxic T CellsMicrobial-specific cytotoxic T lymphocytesAntigen-specific CTLs
02
Targets
pMHC (Peptide-MHC complex family)
Beyond the preview
Go deeper on pathogen-specific CTLs.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pathogen-specific CTLs.